Anna Esteve‐Arenys

The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma

Anna Esteve‐Arenys, Juan García Valero, Aránzazu Chamorro-Jorganes et al. · Oncogene · 2018 · 80 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +10

Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells

Simon C. Body, Anna Esteve‐Arenys, Hadjer Miloudi et al. · Scientific Reports · 2017 · 44 citations · Full text

ZEB1-induced tumourigenesis requires senescence inhibition via activation of DKK1/mutant p53/Mdm2/CtBP and repression of macroH2A1

Oriol de Barrios, Balázs Győrffy, María Jesús Fernández‐Aceñero et al. · Gut · 2016 · 41 citations

Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma

Clara Recasens-Zorzo, Teresa M. Cardesa‐Salzmann, Paolo Petazzi et al. · Haematologica · 2018 · 24 citations · Full text

Immunology, Pathology, Immunotherapy +16

Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma

Elisabeth Höring, Arnau Montraveta, Simon Heine et al. · British Journal of Haematology · 2017 · 15 citations · Full text

Bcl2 Family, Chemoprevention Strategy, Apoptosis +18